Posters presented at the European Hematology Association 2021 Virtual Congress evaluated acute myeloid leukemia (AML) in elderly patients. Although the median age of patients receiving a diagnosis of ...

Sunesis Pharmaceuticals announced the failure of a phase 3 study Monday morning. The company's experimental drug vosaroxin did not extend survival of elderly patients with advanced acute myeloid ...

Please provide your email address to receive an email when new articles are posted on . Over the last 2 decades, 3-year cumulative relapse incidence decreased among elderly patients with AML. OS and 3 ...

Priming GM-CSF and low dose cytarabine (LODAC) in the treatment of high risk and elderly acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) patients This is an ASCO Meeting Abstract ...

BERGEN, Norway, Nov. 7, 2019 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, is ...

BERKELEY HEIGHTS, N.J., Jan. 11, 2011 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), today announced that it has opened enrollment of ...

A randomized phase II study of sapacitabine in MDS refractory to hypomethylating agents. Background: Controversy exists as to how well elderly pts with AML tolerate IC, how to select them for IC vs ...

Elderly patients with acute myeloid leukemia did not experience a difference in relapse-free survival or non-relapse mortality with intensive versus non-intensive chemotherapy. Elderly patients with ...

BOSTON - Older patients with acute myeloid leukemia (AML) often aren't healthy enough to receive intensive chemotherapy, and gentler treatments aren't very effective in treating this aggressive blood ...

BERGEN, Norway, Dec. 9, 2019 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, ...